Pituitary adenylate cyclase activating polypeptide-38
PreclinicalPeptide
Pituitary adenylate cyclase activating polypeptide-38 is one of 27 small molecule programs targeting Headache. It is currently in Preclinical.
2
Indications
3
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
357 competitors in Migraine
#DrugCompanyPhaseTrials
1Aimovig
AmgenPreclinical
Emgality
Eli LillyPreclinical
Vyepti
LundbeckPreclinical
Savella
AbbViePreclinical
Bayer Aspirin
BayerPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Cervidil
PfizerPreclinical
Viagra
VViatris Specialty LLC
Preclinical
Pristiq
PPrism Pharmaceuticals
Preclinical
Bupivacaine Only
Pacira Pharmaceuticals, IncPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Peptide[2]
- Highest Phase
- Preclinical[1]
- Company
- DDanish Headache Center